The Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) was a randomized, double-blind, placebo-controlled trial involving stable patients with previous myocardial infarction; this study evaluated whether canakinumab could prevent recurrent vascular events among those who have a persistent proinflammatory response (high-sensitivity CRP ≥ 2 mg/L) [49]. The gene discussed is CRP; the disease is myocardial infarction.